Biologically defined risk groups can be used to define the impact of thalidomide maintenance therapy in newly diagnosed multiple myeloma.

Item

http://www.wikidata.org/entity/Q44690816

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Biologically defined risk grou ...... ly diagnosed multiple myeloma.

@en

Biologically defined risk grou ...... ly diagnosed multiple myeloma.

@nl

type

Item

label

Biologically defined risk grou ...... ly diagnosed multiple myeloma.

@en

Biologically defined risk grou ...... ly diagnosed multiple myeloma.

@nl

prefLabel

Biologically defined risk grou ...... ly diagnosed multiple myeloma.

@en

Biologically defined risk grou ...... ly diagnosed multiple myeloma.

@nl

P1476

Biologically defined risk grou ...... wly diagnosed multiple myeloma

@en

P2093

Faith E Davies

http://www.w3.org/2001/XMLSchema#string

Fiona M Ross

http://www.w3.org/2001/XMLSchema#string

Graham H Jackson

http://www.w3.org/2001/XMLSchema#string

Martin F Kaiser

http://www.w3.org/2001/XMLSchema#string

Ping Wu

http://www.w3.org/2001/XMLSchema#string

Roger Owen

http://www.w3.org/2001/XMLSchema#string

Walter M Gregory

http://www.w3.org/2001/XMLSchema#string

P2860

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences

Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms.

Lenalidomide after stem-cell transplantation for multiple myeloma

Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results.

IMWG consensus on maintenance therapy in multiple myeloma.

A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial.

Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised p

Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure.

P304

1975-1981

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/10428194.2012.760736

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-01-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23270579

http://www.w3.org/2001/XMLSchema#string

P921

thalidomide